Clinical bottom line
Non-invasive prenatal testing (NIPT) has rapidly expanded beyond screening for common aneuploidies to include detection of monogenic disorders, structural chromosomal abnormalities, and sporadic skeletal dysplasias. While offering safer, earlier, and increasingly comprehensive fetal genetic insights, NIPT’s diagnostic scope remains limited by technical challenges, variable sensitivity for rare conditions, and ethical considerations. Careful patient selection and individualized counseling are essential to optimize clinical utility and minimize false positives or negatives. Ongoing advances in sequencing technology and bioinformatics promise to further enhance NIPT’s accuracy and applicability (Wang et al., 2026; Kim et al., 2026; Hsieh et al., 2025).
What the evidence shows
Wang et al. (2026) review progress in NIPT for monogenic diseases, highlighting targeted sequencing panels that enable detection of single-gene disorders non-invasively. Their analysis underscores improved diagnostic yield but notes challenges including low fetal fraction and maternal variant interference.
Kim et al. (2026) present case reports expanding NIPT’s diagnostic spectrum to structural chromosomal abnormalities, demonstrating feasibility but also emphasizing the need for confirmatory invasive testing due to variable sensitivity and specificity.
Hsieh et al. (2025) discuss the art of individualized NIPT selection, advocating for tailored testing strategies based on maternal risk factors, family history, and clinical context to maximize benefit and reduce unnecessary invasive procedures.
Wang CY et al. (2021) validate an expanded targeted sequencing panel for sporadic skeletal dysplasia diagnosis, illustrating NIPT’s potential in rare disorders but also highlighting technical and interpretative complexities.
Yu et al. (2025) provide a comprehensive overview of NIPT advances, applications, and limitations, emphasizing that while NIPT reduces invasive testing rates, it remains a screening rather than definitive diagnostic tool.
Benn et al. (2016) discuss the expansion of NIPT beyond chromosomes 21, 18, 13, X, and Y, noting that broader panels increase detection of atypical anomalies but also raise challenges in counseling and management.
Caveats and uncertainty
NIPT sensitivity and specificity vary widely for rare monogenic and structural abnormalities.
False positives and negatives remain concerns, necessitating confirmatory invasive testing for positive results.
Interpretation of variants of uncertain significance complicates counseling.
Technical limitations include low fetal DNA fraction and maternal mosaicism.
Ethical issues arise regarding incidental findings and expanded screening scope.
Cost-effectiveness and equitable access to expanded NIPT panels require further evaluation.
How this may change practice
Clinicians should incorporate expanded NIPT options into prenatal care selectively, guided by individualized risk assessment and patient preferences.
Pre- and post-test genetic counseling is critical to address limitations, possible outcomes, and follow-up testing.
Integration of expanded NIPT may reduce invasive procedures but cannot replace diagnostic testing when indicated.
Multidisciplinary collaboration with geneticists and maternal-fetal medicine specialists will optimize interpretation and management.
Ongoing education and guideline updates are needed to keep pace with rapidly evolving NIPT technologies.